The response to vedolizumab in chronic granulomatous disease-related inflammatory bowel disease  

维多珠单抗治疗慢性肉芽肿相关炎症性肠病的疗效

作　　者：Natasha Kamal Beatriz Marciano Bryan Curtin Anna Strongin Suk See DeRavin Athos Bousvaros Christopher Koh Harry L.Malech Steven M.Holland Christa Zerbe Theo Heller 

机构地区：[1]Digestive Disease Branch,National Institute of Diabetes and Digestive and Kidney Diseases,National Institutes of Health,Bethesda,MD,USA [2]Laboratory of Host Defenses,National Institute of Allergy and Infectious Diseases,National Institutes of Health,Bethesda,MD,USA [3]Division of Gastroenterology,Hepatology and Nutrition,Boston Children’s Hospital,Boston,MA,USA [4]Liver Disease Branch,National Institute of Diabetes and Digestive and Kidney Diseases,National Institutes of Health,Bethesda,MD,USA [5]Laboratory of Clinical Immunology and Microbiology,National Institute of Allergy and Infectious Diseases,National Institutes of Health,Bethesda,MD,USA

出　　处：《Gastroenterology Report》2020年第5期404-406,I0003,共4页胃肠病学报道（英文）

基　　金：This work was supported by intramural program at the National Institutes of Health.

摘　　要：Introduction Chronic granulomatous disease(CGD)is a rare immunodeficiency affecting approximately 1 in 200,000 people[1].Patients with CGD are unable to produce normal amounts of neutrophil superoxide and other phagocyte reactive oxygen species.As a result,phagocytes have decreased microbicidal activity and patients develop recurrent bacterial and fungal infections.

关 键 词：慢性肉芽肿 单抗治疗 炎症性肠病 IMMUNODEFICIENCY 

分 类 号：R574[医药卫生—消化系统]